Cell-Demanded Liberation of VEGF121 from Fibrin Implants Induces Local and Controlled Blood Vessel Growth

Martin Ehrbar, Valentin G. Djonov, Christian Schnell, Stefan A. Tschanz, Georg Martiny-Baron, Ursula Schenk, Jeanette Wood, Peter H. Burri, Jeffrey A. Hubbell, Andreas H. Zisch

Research output: Contribution to journalArticle

284 Scopus citations

Abstract

Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: Blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF possesses a binding site for ECM components that maintain it in the immobilized state until released by local cellular enzymatic activity. In this study, we present an engineered variant form of VEGF, α2PI1-8-VEGF121, that mimics this concept of matrix-binding and cell-mediated release by local cell-associated enzymatic activity, working in the surgically-relevant biological matrix fibrin. We show that matrix-conjugated α2PI1-8-VEGF 121 is protected from clearance, contrary to native VEGF 121 mixed into fibrin, which was completely released as a passive diffusive burst. Grafting studies on the embryonic chicken chorioallantoic membrane (CAM) and in adult mice were performed to assess and compare the quantity and quality of neovasculature induced in response to fibrin implants formulated with matrix-bound α2PI1-8-VEGF 121 or native diffusible VEGF121. Our CAM measurements demonstrated that cell-demanded release of α2PI1-8-VEGF 121 increases the formation of new arterial and venous branches, whereas exposure to passively released wild-type VEGF121 primarily induced chaotic changes within the capillary plexus. Specifically, our analyses at several levels, from endothelial cell morphology and endothelial interactions with periendothelial cells, to vessel branching and network organization, revealed that α2PI1-8-VEGF 121 induces vessel formation more potently than native VEGF 121 and that those vessels possess more normal morphologies at the light microscopic and ultrastructural level. Permeability studies in mice validated that vessels induced by α2PI1-8-VEGF 121 do not leak. In conclusion, cell-demanded release of engineered VEGF121 from fibrin implants may present a therapeutically safe and practical modality to induce local angiogenesis.

Original languageEnglish (US)
Pages (from-to)1124-1132
Number of pages9
JournalCirculation research
Volume94
Issue number8
DOIs
StatePublished - Apr 30 2004

Keywords

  • Controlled release
  • Fibrin
  • Therapeutic angiogenesis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Cell-Demanded Liberation of VEGF<sub>121</sub> from Fibrin Implants Induces Local and Controlled Blood Vessel Growth'. Together they form a unique fingerprint.

  • Cite this

    Ehrbar, M., Djonov, V. G., Schnell, C., Tschanz, S. A., Martiny-Baron, G., Schenk, U., Wood, J., Burri, P. H., Hubbell, J. A., & Zisch, A. H. (2004). Cell-Demanded Liberation of VEGF121 from Fibrin Implants Induces Local and Controlled Blood Vessel Growth. Circulation research, 94(8), 1124-1132. https://doi.org/10.1161/01.RES.0000126411.29641.08